FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemVolker Brinkmann|British Journal of Pharmacology|2009Cited by 437
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).Jerold Chun, Volker Brinkmann|PubMed|2011Cited by 179
Sphingosine-1-Phosphate Stimulates the Functional Capacity of Progenitor Cells by Activation of the CXCR <sub>4</sub> -Dependent Signaling Pathway via the S1P <sub>3</sub> ReceptorDirk Walter, Judith Haendeler, Ulrich Rochwalsky et al.|Arteriosclerosis Thrombosis and Vascular Biology|2006Cited by 161
Midkine drives cardiac inflammation by promoting neutrophil trafficking and NETosis in myocarditisLudwig T. Weckbach, Barbara Walzog, Karin Klingel et al.|The Journal of Experimental Medicine|2019Cited by 133
Analysis of sphingosine 1‐phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological toolsSalvatore Salomone, Christian Waeber, Essie M. Potts et al.|British Journal of Pharmacology|2007Cited by 126